Jeremy Slivnick, MD, spoke with Cardiovascular Business about AI's potential to transform how cardiac amyloidosis is diagnosed and treated. 

NYU Grossman School of Medicine researchers used artificial intelligence and wearable activity trackers to improve the monitoring and classification of older adult cardiac rehabilitation patients.

For this update to be finalized, the American Medical Association had to determine FFR_CT Analysis met certain requirements in terms of its overall impact on patient care. John Farquhar, CEO of HeartFlow, described the news as "a win for everyone involved, most notably patients." 

Researchers think this represents a potential breakthrough for low- and middle-income countries where access to high-quality imaging evaluations is still limited. 

By focusing more on inflammation, cardiologists can ensure they are identifying patients who need help before it's too late.

Improving care for patients with cardiac amyloidosis has emerged as one of the hottest topics in cardiology. Pfizer helped kickstart that trend in 2019 when it gained FDA approval for two separate medications for the rare, but potentially fatal disease. 

Advanced AI models can evaluate a patient's heart failure risk using 12-lead ECG data—but there is still some room for improvement. 

The company's trademark offering has now been used to evaluate one quarter of a million patients.